Summary
Johnson & Johnson reported its second-quarter 2015 results, showing a decrease in worldwide sales to $17.79 billion, down 8.8% from the prior year, primarily due to negative currency impacts and the divestiture of the Ortho-Clinical Diagnostics business. Operationally, sales declined by 0.9%, with significant impacts from competitive products in the Hepatitis C market. Despite the sales decline, net earnings increased to $4.52 billion from $4.33 billion in the prior year's second quarter, resulting in diluted earnings per share of $1.61, up from $1.51. The company generated strong operating cash flow of $8.07 billion for the first six months of the year. Significant gains on asset sales, including the divestiture of NUCYNTA® license rights, positively impacted "Other Income (Expense), net" and boosted pre-tax profit in the Pharmaceutical segment. However, the Medical Devices segment saw a significant sales decline, largely due to the divestiture of the Ortho-Clinical Diagnostics business and continued pricing pressures.
Financial Highlights
53 data points| Revenue | $17.79B |
| Cost of Revenue | $5.36B |
| Gross Profit | $12.43B |
| SG&A Expenses | $5.38B |
| Interest Expense | $131.00M |
| Net Income | $4.52B |
| EPS (Basic) | $1.63 |
| EPS (Diluted) | $1.61 |
| Shares Outstanding (Basic) | 2.77B |
| Shares Outstanding (Diluted) | 2.81B |
Key Highlights
- 1Worldwide sales decreased by 8.8% to $17.79 billion for the second quarter of 2015 compared to the prior year, impacted by currency fluctuations and divestitures.
- 2Net earnings increased to $4.52 billion in the second quarter, with diluted EPS rising to $1.61 from $1.51 in the prior year.
- 3Operating cash flow remained robust, generating $8.07 billion for the first six months of the year.
- 4The Pharmaceutical segment saw operational sales growth of 1.0% in Q2, driven by strong performance in Oncology and Cardiovascular/Metabolism/Other, although impacted by Hepatitis C product competition.
- 5The Medical Devices segment experienced a significant sales decline of 12.2% due to the divestiture of Ortho-Clinical Diagnostics and ongoing market challenges.
- 6The company announced its intention to acquire the Cordis business from Cardinal Health, valued at approximately $2.0 billion, expected to close in the latter half of 2015.
- 7Johnson & Johnson continued to return capital to shareholders through dividends ($0.75 per share declared) and share repurchases, completing a $5.0 billion repurchase program.